We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina (ILMN) Strong on Product Launches, Competition Rife
Read MoreHide Full Article
On Oct 9, we issued an updated research report on Illumina, Inc. (ILMN - Free Report) . The stock currently carries a Zacks Rank #3 (Hold).
Over the last three months, this San Diego, CA-based company providing tools and integrated systems for the analysis of genetic variation and function, has been trading above the broader industry. The stock has gained 17.4% in this period, higher than the broader industry’s 7.9% gain.
Over the past few quarters, the company has delivered promising top-line performances primarily banking on strong product launches. The latest in the list includes the launch of VeriSeq NIPT Solution in Europe. Also overall strong uptake in NovaSeq is encouraging. Moreover, the rate of NIPT adoption is rising outside the United States.
We are also upbeat about Illumina’s partnership with Telegraph Hill Partners to set up an independent company Verogen, Inc. The independent company is expected to boost Illumina’s next-generation sequencing (NGS) business in the forensic genomics market. Along with having global commercial rights to these products, Illumina will be the only provider of the MiSeq FGx Forensic Genomics System, including the MiSeq FGx sequencer, ForenSeq DNA Signature Prep Kit and the ForenSeq Universal Analysis Software.
We are encouraged by the developments within the clinical markets where demand from customers undergoing oncology tests remains robust. Moreover, investors are awaiting response to the Extended RAS Panel which is slated for launch in the third quarter. In June, the company announced the receipt of FDA approval for the Extended RAS companion diagnostic kit (as the Class III PMA).
We are also looking forward to GRAIL, Illumina’s own-developed company, focused on the cancer screening market.
On the flip side, weak margins due to the NovaSeq launch, higher array service revenues and product mix within sequencing consumables continue to raise concerns. Also, the National Institutes of Health (NIH) funding issue and a tough competitive landscape are a few challenges to deal with.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock has rallied roughly 25.4% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained 40.3% last year.
Thermo Fisher has a long-term expected earnings growth rate of 16.3%. The stock has gained 24.8% last year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Illumina (ILMN) Strong on Product Launches, Competition Rife
On Oct 9, we issued an updated research report on Illumina, Inc. (ILMN - Free Report) . The stock currently carries a Zacks Rank #3 (Hold).
Over the last three months, this San Diego, CA-based company providing tools and integrated systems for the analysis of genetic variation and function, has been trading above the broader industry. The stock has gained 17.4% in this period, higher than the broader industry’s 7.9% gain.
Over the past few quarters, the company has delivered promising top-line performances primarily banking on strong product launches. The latest in the list includes the launch of VeriSeq NIPT Solution in Europe. Also overall strong uptake in NovaSeq is encouraging. Moreover, the rate of NIPT adoption is rising outside the United States.
We are also upbeat about Illumina’s partnership with Telegraph Hill Partners to set up an independent company Verogen, Inc. The independent company is expected to boost Illumina’s next-generation sequencing (NGS) business in the forensic genomics market. Along with having global commercial rights to these products, Illumina will be the only provider of the MiSeq FGx Forensic Genomics System, including the MiSeq FGx sequencer, ForenSeq DNA Signature Prep Kit and the ForenSeq Universal Analysis Software.
We are encouraged by the developments within the clinical markets where demand from customers undergoing oncology tests remains robust. Moreover, investors are awaiting response to the Extended RAS Panel which is slated for launch in the third quarter. In June, the company announced the receipt of FDA approval for the Extended RAS companion diagnostic kit (as the Class III PMA).
We are also looking forward to GRAIL, Illumina’s own-developed company, focused on the cancer screening market.
On the flip side, weak margins due to the NovaSeq launch, higher array service revenues and product mix within sequencing consumables continue to raise concerns. Also, the National Institutes of Health (NIH) funding issue and a tough competitive landscape are a few challenges to deal with.
Key Picks
A few better-ranked stocks in the medical sector are Abbott (ABT - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Thermo Fisher Scientific Inc. (TMO - Free Report) , with a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock has rallied roughly 25.4% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained 40.3% last year.
Thermo Fisher has a long-term expected earnings growth rate of 16.3%. The stock has gained 24.8% last year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>